Oil & Gas Refining & Marketing
Compare Stocks
5 / 10Stock Comparison
CLNE vs UGI vs AMTX vs GEVO vs REX
Revenue, margins, valuation, and 5-year total return — side by side.
Regulated Gas
Oil & Gas Refining & Marketing
Chemicals - Specialty
Chemicals - Specialty
CLNE vs UGI vs AMTX vs GEVO vs REX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Oil & Gas Refining & Marketing | Regulated Gas | Oil & Gas Refining & Marketing | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $507M | $6.94B | $213M | $493M | $1.60B |
| Revenue (TTM) | $439M | $7.36B | $209M | $174M | $651M |
| Net Income (TTM) | $-99M | $641M | $-74M | $-11M | $50M |
| Gross Margin | 11.7% | 30.3% | 3.4% | 23.4% | 12.7% |
| Operating Margin | 7.4% | 15.4% | -13.4% | -4.6% | 8.6% |
| Forward P/E | — | 10.6x | — | — | 62.8x |
| Total Debt | $99M | $7.56B | $318M | $168M | $21M |
| Cash & Equiv. | $158M | $355M | $5M | $1M | $196M |
CLNE vs UGI vs AMTX vs GEVO vs REX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Clean Energy Fuels … (CLNE) | 100 | 110.5 | +10.5% |
| UGI Corporation (UGI) | 100 | 101.5 | +1.5% |
| Aemetis, Inc. (AMTX) | 100 | 390.0 | +290.0% |
| Gevo, Inc. (GEVO) | 100 | 157.4 | +57.4% |
| REX American Resour… (REX) | 100 | 498.3 | +398.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CLNE vs UGI vs AMTX vs GEVO vs REX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CLNE lags the leaders in this set but could rank higher in a more targeted comparison.
UGI carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 0 yrs, beta 0.27, yield 4.5%
- Better valuation composite
- 8.7% margin vs AMTX's -35.4%
- Beta 0.27 vs GEVO's 1.64
Among these 5 stocks, AMTX doesn't own a clear edge in any measured category.
GEVO ranks third and is worth considering specifically for growth exposure.
- Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
- 8.5% revenue growth vs REX's -22.9%
REX is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 464.7% 10Y total return vs UGI's 9.6%
- Lower volatility, beta 0.36, Low D/E 3.3%, current ratio 8.64x
- PEG 1.18 vs UGI's 2.60
- Beta 0.36, current ratio 8.64x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.5% revenue growth vs REX's -22.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 8.7% margin vs AMTX's -35.4% | |
| Stability / Safety | Beta 0.27 vs GEVO's 1.64 | |
| Dividends | 4.5% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +147.6% vs UGI's +0.7% | |
| Efficiency (ROA) | 6.7% ROA vs AMTX's -29.3%, ROIC 11.4% vs -70.3% |
CLNE vs UGI vs AMTX vs GEVO vs REX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CLNE vs UGI vs AMTX vs GEVO vs REX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UGI leads in 2 of 6 categories
REX leads 2 • CLNE leads 0 • AMTX leads 0 • GEVO leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UGI leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UGI is the larger business by revenue, generating $7.4B annually — 42.2x GEVO's $174M. UGI is the more profitable business, keeping 8.7% of every revenue dollar as net income compared to AMTX's -35.4%. On growth, GEVO holds the edge at +47.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $439M | $7.4B | $209M | $174M | $651M |
| EBITDAEarnings before interest/tax | $62M | $1.7B | -$21M | $18M | $67M |
| Net IncomeAfter-tax profit | -$99M | $641M | -$74M | -$11M | $50M |
| Free Cash FlowCash after capex | $19M | $629M | -$38M | -$35M | $18M |
| Gross MarginGross profit ÷ Revenue | +11.7% | +30.3% | +3.4% | +23.4% | +12.7% |
| Operating MarginEBIT ÷ Revenue | +7.4% | +15.4% | -13.4% | -4.6% | +8.6% |
| Net MarginNet income ÷ Revenue | -22.7% | +8.7% | -35.4% | -6.6% | +7.7% |
| FCF MarginFCF ÷ Revenue | +4.3% | +8.5% | -18.2% | -19.9% | +2.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.3% | +0.7% | +27.4% | +47.5% | +0.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +90.0% | +6.4% | +29.8% | +3.8% | +2.9% |
Valuation Metrics
UGI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 10.5x trailing earnings, UGI trades at a 65% valuation discount to REX's 29.5x P/E. Adjusting for growth (PEG ratio), REX offers better value at 0.55x vs UGI's 2.56x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $507M | $6.9B | $213M | $493M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $448M | $14.1B | $526M | $659M | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.29x | 10.46x | -2.44x | -14.50x | 29.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.62x | — | — | 62.81x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.56x | — | — | 0.55x |
| EV / EBITDAEnterprise value multiple | 94.64x | 8.48x | — | 102.12x | 16.60x |
| Price / SalesMarket cap ÷ Revenue | 1.19x | 0.95x | 1.02x | 3.07x | 2.50x |
| Price / BookPrice ÷ Book value/share | 0.90x | 1.48x | — | 1.01x | 2.67x |
| Price / FCFMarket cap ÷ FCF | 8.47x | 17.80x | — | — | — |
Profitability & Efficiency
REX leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
UGI delivers a 12.8% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-17 for CLNE. REX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to UGI's 1.58x. On the Piotroski fundamental quality scale (0–9), CLNE scores 5/9 vs GEVO's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.2% | +12.8% | — | -2.4% | +7.7% |
| ROA (TTM)Return on assets | -9.2% | +4.1% | -29.3% | -1.7% | +6.7% |
| ROICReturn on invested capital | -9.4% | +7.1% | -70.3% | -2.8% | +11.4% |
| ROCEReturn on capital employed | -9.4% | +8.3% | -19.0% | -3.1% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.18x | 1.58x | — | 0.36x | 0.03x |
| Net DebtTotal debt minus cash | -$59M | $7.2B | $313M | $166M | -$175M |
| Cash & Equiv.Liquid assets | $158M | $355M | $5M | $1M | $196M |
| Total DebtShort + long-term debt | $99M | $7.6B | $318M | $168M | $21M |
| Interest CoverageEBIT ÷ Interest expense | -1.07x | 2.69x | -0.27x | -0.04x | — |
Total Returns (Dividends Reinvested)
REX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REX five years ago would be worth $34,996 today (with dividends reinvested), compared to $2,387 for AMTX. Over the past 12 months, REX leads with a +147.6% total return vs UGI's +0.7%. The 3-year compound annual growth rate (CAGR) favors REX at 50.8% vs CLNE's -18.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.9% | -13.1% | +96.2% | -1.5% | +50.2% |
| 1-Year ReturnPast 12 months | +44.4% | +0.7% | +140.0% | +88.0% | +147.6% |
| 3-Year ReturnCumulative with dividends | -46.3% | +22.3% | +37.4% | +65.0% | +243.1% |
| 5-Year ReturnCumulative with dividends | -73.8% | -13.1% | -76.1% | -65.2% | +250.0% |
| 10-Year ReturnCumulative with dividends | -26.9% | +9.6% | +31.1% | -98.6% | +464.7% |
| CAGR (3Y)Annualised 3-year return | -18.7% | +6.9% | +11.2% | +18.2% | +50.8% |
Risk & Volatility
Evenly matched — UGI and REX each lead in 1 of 2 comparable metrics.
Risk & Volatility
UGI is the less volatile stock with a 0.27 beta — it tends to amplify market swings less than GEVO's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REX currently trades 91.2% from its 52-week high vs GEVO's 68.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 0.27x | 1.46x | 1.64x | 0.36x |
| 52-Week HighHighest price in past year | $3.11 | $41.34 | $3.80 | $2.97 | $53.36 |
| 52-Week LowLowest price in past year | $1.56 | $31.62 | $1.22 | $1.01 | $19.44 |
| % of 52W HighCurrent price vs 52-week peak | +74.3% | +78.2% | +82.1% | +68.4% | +91.2% |
| RSI (14)Momentum oscillator 0–100 | 44.6 | 37.1 | 58.2 | 53.5 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 1.5M | 1.8M | 4.5M | 204K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CLNE as "Buy", UGI as "Buy", AMTX as "Buy", GEVO as "Buy", REX as "Buy". Consensus price targets imply 72.4% upside for GEVO (target: $4) vs -43.9% for AMTX (target: $2). UGI is the only dividend payer here at 4.55% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $3.50 | $42.00 | $1.75 | $3.50 | $60.00 |
| # AnalystsCovering analysts | 22 | 10 | 7 | 14 | 3 |
| Dividend YieldAnnual dividend ÷ price | — | +4.5% | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | $1.47 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | +0.5% | 0.0% | 0.0% | +0.9% |
UGI leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). REX leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
CLNE vs UGI vs AMTX vs GEVO vs REX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CLNE or UGI or AMTX or GEVO or REX a better buy right now?
For growth investors, Gevo, Inc.
(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -22. 9% for REX American Resources Corporation (REX). UGI Corporation (UGI) offers the better valuation at 10. 5x trailing P/E (10. 6x forward), making it the more compelling value choice. Analysts rate Clean Energy Fuels Corp. (CLNE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CLNE or UGI or AMTX or GEVO or REX?
On trailing P/E, UGI Corporation (UGI) is the cheapest at 10.
5x versus REX American Resources Corporation at 29. 5x. On forward P/E, UGI Corporation is actually cheaper at 10. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: REX American Resources Corporation wins at 1. 18x versus UGI Corporation's 2. 60x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — CLNE or UGI or AMTX or GEVO or REX?
Over the past 5 years, REX American Resources Corporation (REX) delivered a total return of +250.
0%, compared to -76. 1% for Aemetis, Inc. (AMTX). Over 10 years, the gap is even starker: REX returned +464. 7% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CLNE or UGI or AMTX or GEVO or REX?
By beta (market sensitivity over 5 years), UGI Corporation (UGI) is the lower-risk stock at 0.
27β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 517% more volatile than UGI relative to the S&P 500. On balance sheet safety, REX American Resources Corporation (REX) carries a lower debt/equity ratio of 3% versus 158% for UGI Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CLNE or UGI or AMTX or GEVO or REX?
By revenue growth (latest reported year), Gevo, Inc.
(GEVO) is pulling ahead at 849. 3% versus -22. 9% for REX American Resources Corporation (REX). On earnings-per-share growth, the picture is similar: UGI Corporation grew EPS 147. 2% year-over-year, compared to -173. 0% for Clean Energy Fuels Corp.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CLNE or UGI or AMTX or GEVO or REX?
UGI Corporation (UGI) is the more profitable company, earning 9.
3% net margin versus -52. 3% for Clean Energy Fuels Corp. — meaning it keeps 9. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UGI leads at 15. 2% versus -22. 1% for CLNE. At the gross margin level — before operating expenses — UGI leads at 49. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CLNE or UGI or AMTX or GEVO or REX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, REX American Resources Corporation (REX) is the more undervalued stock at a PEG of 1. 18x versus UGI Corporation's 2. 60x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, UGI Corporation (UGI) trades at 10. 6x forward P/E versus 62. 8x for REX American Resources Corporation — 52. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GEVO: 72. 4% to $3. 50.
08Which pays a better dividend — CLNE or UGI or AMTX or GEVO or REX?
In this comparison, UGI (4.
5% yield) pays a dividend. CLNE, AMTX, GEVO, REX do not pay a meaningful dividend and should not be held primarily for income.
09Is CLNE or UGI or AMTX or GEVO or REX better for a retirement portfolio?
For long-horizon retirement investors, UGI Corporation (UGI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
27), 4. 5% yield). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UGI: +9. 6%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CLNE and UGI and AMTX and GEVO and REX?
These companies operate in different sectors (CLNE (Energy) and UGI (Utilities) and AMTX (Energy) and GEVO (Basic Materials) and REX (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CLNE is a small-cap quality compounder stock; UGI is a small-cap deep-value stock; AMTX is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock; REX is a small-cap quality compounder stock. UGI pays a dividend while CLNE, AMTX, GEVO, REX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.